Quantcast

Latest Aripiprazole Stories

2010-01-04 16:21:16

Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals. In 2003, the Food and Drug Administration (FDA) began requiring a warning on labels of second-generation...

2009-12-02 07:00:00

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Schizophrenia finds that the...

2009-11-05 07:00:00

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that widespread generic erosion of branded atypical antipsychotics will cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to approximately $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Bipolar Disorder finds that the...

69ebba93937a01a1551131e73148d2ae1
2009-10-29 12:41:05

A new study has shown that antipsychotic drugs may be linked to weight gain in kids. Writing in the Journal of the American Medical Association (JAMA), researchers studied the use of name-brand second-generation anti-psychotic drugs, including Abilify, Risperdal, Seroquel and Zyprexa, in 272 kids aged 4 to 19 years. Children involved in the study had not been previously treated with anti-psychotic drugs. "First-time second-generation antipsychotic medication use was associated with...

2009-10-27 16:25:53

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA. Treatment for psychotic disorders, bipolar disorder, and nonpsychotic mental disorders for children and adolescents in the United States often includes second-generation antipsychotic medications....

2009-07-23 07:00:00

WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to risperidone (Janssen's Risperdal, generics) in first and second lines of therapy and leads other...

2009-06-22 10:00:00

Although Risperidone Is Now Available In Generics, There Is No Clear Evidence of Expanded Uptake in Early Lines of Therapy, According to a New Report from Decision Resources Patient-Flow Forecasts Need to Take Into Account Shifts in Seroquel XR's Use by Line of Therapy Over the Next Two Years WALTHAM, Mass., June 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that AstraZeneca Seroquel's...

2009-04-27 08:00:00

Lamictal Will Retain Decision Resources' Clinical Gold Standard Status for Bipolar Depression, According to a New Report from Decision Resources WALTHAM, Mass., April 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists identify a therapy's effect on decrease in severity of depressive symptoms as the attribute that most influences their prescribing decisions in bipolar...

2009-02-12 07:00:00

Altmeyer brings extensive experience in neuroscience and oncology to OAPI, further strengthening the company's growth in these therapeutic categories ROCKVILLE, Md. and PRINCETON, N.J., Feb. 12 /PRNewswire/ -- Otsuka America Pharmaceutical, Inc. (OAPI), a fast-growing health care company that commercializes Otsuka-discovered and other product opportunities in North America, has announced the appointment of Mark Altmeyer as President and Chief Executive Officer. Altmeyer succeeds Interim...

2008-12-03 07:00:00

WALTHAM, Mass., Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the modest introduction of emerging therapies in the bipolar depression market will not compensate for extensive generic erosion of branded agents, resulting in a decrease of just over $1 billion in drug sales through 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related